Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MRNA-seq of zebrafish treated with sex hormone 17β-estradiol and aromatase inhibitor exemestane during sex development

ABSTRACT: mRNA-seq of zebrafish treated with sex hormone 17β-estradiol and aromatase inhibitor exemestane during sex development

PROVIDER: PRJNA520845 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8526610_1.fastq.gz	Fastqsanger.gz
	SRR8526610_2.fastq.gz	Fastqsanger.gz
	SRR8526620_1.fastq.gz	Fastqsanger.gz
	SRR8526620_2.fastq.gz	Fastqsanger.gz
	SRR8526630_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 112

Similar Datasets

mRNA-seq of zebrafish treated with sex hormone 17β-estradiol and aromatase inhibitor exemestane during sex development

Project description:To identify key genes in the early sex development of zebrafish, we generated zebrafish (AB strain) feminized by sex hormone 17β-estradiol (E2, CAS: 50-28-2, 100 ng/L) and masculinized by aromatase inhibitor exemestane (EM, CAS: 107868-30-4, 10 μg/L), and detected their transcriptomes by RNA-seq.

2022-05-11 | GSE126039 | GEO

mRNA-seq of zebrafish treated with sex hormone 17β-estradiol and aromatase inhibitor exemestane at 12dpf (mixed species RNA preparation prepared with Drosophila S2 cell RNA)

Project description:mRNA-seq of zebrafish treated with sex hormone 17β-estradiol and aromatase inhibitor exemestane at 12dpf (mixed species RNA preparation prepared with Drosophila S2 cell RNA)

| PRJNA545899 | ENA

mRNA-seq of gonads from adult zebrafish treated with aromatase inhibitor and control

Project description:To explore the transcriptional effects of aromatase inhibitors on sex differentiation of zebrafish, we exposed 3-month-old zebrafish (AB strain) to the third generation aromatase inhibitor Exemestane (CAS: 107868-30-4) and characterized transcript abundance among testes and ovaries after 32 days of drug exposure. After the drug treatment, we dissected zebrafish gonads, isolated polyA+ RNA and performed high-throughput RNA-Seq analysis.

2019-12-07 | GSE123439 | GEO

Danio rerio strain:AB

Project description:mRNA-seq of zebrafish treated with sex hormone 17β-estradiol and aromatase inhibitor exemestane during sex development

| PRJNA518034 | ENA

Εarly transcriptional effects of 17β-estradiol, 17β-estradiol-BSA and tamoxifen in human NSCLC cell lines A549 and H520

Project description:Assessment of different subcellular localizations (membrane, cytosol, nucleus) of estrogen receptors by multi-epitope protein expression in 200 NSCLC specimens and matched non-cancerous tissues and ESR-1 probe mapping meta-analysis of Affymetrix 2.0 plus data in 1398 NSCLC tumors and normal lung tissues and 39 NSCLC cell lines led us to the conclusion that ERα extranuclear variants are the main ERs in NSCLC. In order to further analyze these effects we treated A549 and H520 cell lines with 17β-estradiol, 17β-estradiol-BSA (plasma membrane impermeable conjugate) and tamoxifen for 3h, in order to investigate early transcriptional effects and responsiveness to estrogen agonists and antagonists. The aim of this study was to demonstrate the functionality of NSCLC ERs and decipher which genes, canonical pathways and networks are affected by each treatment.

2016-12-22 | GSE92679 | GEO

Time course experiment of 17β-estradiol (E2) treatment in the zebrafish

Project description:Transcriptional profiling of zebrafish (Danio rerio) livers comparing control untreated fish with fish treated with estrogen [17β-estradiol (E2)] for different time points (4, 12, 24, 48 hours).

2013-06-28 | GSE45562 | GEO

Transcriptome of juvenile zebrafish treated with the aromatase inhibitor exemestane and solvent control

Project description:To reveal the transcriptomic changes during the sex differetiation in larval zebrafish, we treated the lavarl fish with aromatase inhibitors (EM, CAS: 107868-30-4, 100 μg/L), as well as solvent as a control, and sampled them after the exposure.

2019-12-20 | GSE142353 | GEO

Pembrolizumab, exemestane, and leuprolide in premenopausal estrogen receptor-positive/HER2-negative advanced breast cancer

Project description:We evaluated the efficacy of combining pembrolizumab (anti-PD1 antibody), exemestane (nonsteroidal aromatase inhibitor), and leuprolide (gonadotropin-releasing hormone agonist) for 15 patients with ER+/HER2− premenopausal MBC who had failed one to two lines of hormone therapy without chemotherapy.

2024-10-28 | GSE261380 | GEO

To elucidate the role of estradiol- 17β (E2) in the regulation of corpus luteum function

Project description:Corpus luteum (CL) is a transient endocrine tissue formed from the remnants of the ovarian follicle after ovulation. In response to gonadotropin surge, the ovulating follicle undergoes dramatic changes in expression of genes and differentiation of follicular cells into luteal cells. In several species, of the several genes that are down- regulated post ovulation, Cyp19A1 that codes for aromatase, essential for biosynthesis of estradiol- 17β (E2), also get down- regulated but appears to get up- regulated at later time points in the estrous cycle to have critical role in E2 secretion. In primates and rodents, higher expression and higher E2 levels has been observed in CL. Surprisingly, in the recently carried out gene expression profiling of PGF2α- induced luteolysis studies in the bovine species [GSE27961], it was observed that expression of one of the earliest genes that was down- regulated was Cyp19A1 in the CL. However, the specific role of E2 in the regulation of CL function remains poorly defined. Thus, in the present study, efforts were made to examine the temporal changes in the global gene expression profile in the CL of pregnant rats after treatment with aromatase inhibitor (AI), Anastrozole, and E2 supplementation. The results obtained will further expand our knowledge on E2 target/responsive genes and the basic mechanism(s) that regulates the CL function. Key words: CL, E2, AI, Gene expression

2012-10-23 | GSE41735 | GEO

Immune microenvironment of premenopausal estrogen receptor-positive/HER2-negative advanced breast cancer in response to treatment of Pembrolizumab, exemestane, and leuprolide

2024-10-28 | GSE261815 | GEO